Ocular Therapeutix appoints Michael Goldstein as CMO

US ophthalmology specialist Ocular Therapeutix (Nasdaq: OCUL) today announced the appointment of Michael Goldstein as chief medical officer.

Dr Goldstein is a highly-accomplished ophthalmologist, having held several senior medical leadership positions with ophthalmology-focused pharmaceutical companies and published extensively in multiple ophthalmology scientific journals. In his new role, Dr Goldstein will oversee the clinical development of the company’s product pipeline.

“We are pleased to further strengthen our executive leadership team with the appointment of Mike as our chief medical officer,” said Antony Mattessich, chief executive, adding: “Mike brings a deep expertise in both biopharmaceuticals and ophthalmology, and possesses the vision and clinical leadership skills required to realize the Ocular’s full potential. His experience will be critical as we prepare to initiate multiple clinical trials, including our second Phase III trial with OTX-TP for the treatment of glaucoma and hypertension, our pilot human clinical trial with OTX-TIC for the treatment of glaucoma and hypertension, and our Phase I clinical trial with OTX-TKI for the treatment of serious retinal diseases.